ProShare Advisors’s Vaxcyte PCVX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $995K | Sell |
30,609
-2,083
| -6% | -$67.7K | ﹤0.01% | 821 |
|
|
2025
Q1 | $1.23M | Sell |
32,692
-8,183
| -20% | -$309K | ﹤0.01% | 757 |
|
|
2024
Q4 | $3.35M | Buy |
40,875
+11,729
| +40% | +$960K | 0.01% | 591 |
|
|
2024
Q3 | $3.33M | Buy |
29,146
+8,212
| +39% | +$938K | 0.01% | 596 |
|
|
2024
Q2 | $1.58M | Sell |
20,934
-5,733
| -21% | -$433K | ﹤0.01% | 695 |
|
|
2024
Q1 | $1.82M | Buy |
26,667
+5,060
| +23% | +$346K | ﹤0.01% | 678 |
|
|
2023
Q4 | $1.36M | Buy |
21,607
+3,285
| +18% | +$206K | ﹤0.01% | 699 |
|
|
2023
Q3 | $934K | Buy |
18,322
+302
| +2% | +$15.4K | ﹤0.01% | 736 |
|
|
2023
Q2 | $900K | Buy |
18,020
+4,030
| +29% | +$201K | ﹤0.01% | 750 |
|
|
2023
Q1 | $524K | Sell |
13,990
-1,770
| -11% | -$66.3K | ﹤0.01% | 893 |
|
|
2022
Q4 | $756K | Buy |
15,760
+4,833
| +44% | +$232K | ﹤0.01% | 803 |
|
|
2022
Q3 | $262K | Buy |
10,927
+464
| +4% | +$11.1K | ﹤0.01% | 1229 |
|
|
2022
Q2 | $228K | Sell |
10,463
-3,364
| -24% | -$73.3K | ﹤0.01% | 1391 |
|
|
2022
Q1 | $334K | Sell |
13,827
-2,428
| -15% | -$58.7K | ﹤0.01% | 1550 |
|
|
2021
Q4 | $387K | Sell |
16,255
-72
| -0.4% | -$1.71K | ﹤0.01% | 1629 |
|
|
2021
Q3 | $414K | Sell |
16,327
-3,217
| -16% | -$81.6K | ﹤0.01% | 1324 |
|
|
2021
Q2 | $440K | Buy |
19,544
+4,750
| +32% | +$107K | ﹤0.01% | 1617 |
|
|
2021
Q1 | $292K | Buy |
14,794
+2,897
| +24% | +$57.2K | ﹤0.01% | 1822 |
|
|
2020
Q4 | $316K | Buy |
+11,897
| New | +$316K | ﹤0.01% | 1579 |
|